Drugs / BX004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06998043 | Jul 2025 → Mar 2026 overdue | Pseudomonas aeruginosa infectious disease, cystic fibrosis | BiomX, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BX004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998043 ↗ |
| Modality | Other / unclassified | “Bacteriophage” NCT06998043 ↗ |
| Route | Inhaled | “nebulized phage (BX004)” NCT06998043 ↗ |